M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact BioSpaceMerck will use Protillion Biosciences' tech to design biologic therapies for therapies across undisclosed indications.Read full story pharminent June 17, 2026 (Last updated: June 17, 2026) BioSpace Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Moderna builds commercial muscle as new launches loomNext: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short Related Stories M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera pharminent June 17, 2026 M&A / Deals Altaris to acquire Simulations Plus in $375m all-cash deal pharminent June 17, 2026 M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026
